On December 15, Changchun High-tech Kinsai Pharmaceutical's Global Science and Technology Innovation Headquarters and R&D Center held a groundbreaking and groundbreaking ceremony in Shanghai Zhangjiang International Medical Park. With the launch of the Shanghai Global R&D Center, Kinsey Pharmaceuticals will continue to promote the integrated development of industry, academia, research and medicine through the differentiated innovation brought by leading R&D technology platforms and artificial intelligence technologies, provide the world's best solutions for women's and children's health, and truly realize the beautiful vision of protecting children's and women's health with science and technology.
Construction of Zhangjiang R&D Center
It is a continuation of Kinsey's independent innovation strategy
Based on the in-depth interpretation of national policies and the capture of health needs, Kinsey Pharmaceuticals gives full play to its own advantages, builds a leading technology platform, and promotes the research and development of global innovative products. It has formed a product matrix that runs through the whole process of screening, detection, prevention, treatment and rehabilitation, and has the global development capabilities of innovative products such as biological drugs, chemical drugs, special preparations, live bacteria drugs, medical devices and nutritional and health foods. Dr. Jin Lei, General Manager and Chief Scientist of Kinsey Pharmaceutical, pointed out: "All product innovations of our company must have significant differentiation advantages, and the construction of Zhangjiang R&D Center is a continuation of Kinsey's independent innovation strategy. ”
It is reported that since its establishment in 1997, Kinsey has successively launched the world's first polyethylene glycol long-acting recombinant human growth hormone, the first domestic recombinant human follicle-stimulating hormone, and the world's first recombinant human granulocyte-stimulating factor gel, bringing hope to children with growth retardation and infertility patients. With the excellent efficacy and outstanding contribution of original products in the field of children's growth and development, the project of "Development and Industrialization of Recombinant Human Growth Hormone Series Products" of Jinsai Pharmaceutical won the second prize of the 2015 National Science and Technology Progress Award, demonstrating the strength of independent innovation of Chinese enterprises. Subsequently, the company entered the fast lane of development and rapidly grew into one of the leading enterprises in the biopharmaceutical industry, with annual revenue exceeding 10 billion yuan, and R&D investment accounting for nearly 20% of revenue in the first three quarters of 2023, ranking among the top 10 in the "2023 China Biopharmaceutical R&D Strength Ranking".
At present, Kinsey has moved from growth hormone to a new stage of blooming around children's health and women's health. Dr. Jin Lei said: "We have established a globally innovative and competitive R&D product pipeline, and by 2025, Kinsey will have a very rich product pipeline, with more than 4 leading innovative drugs and more than 5 innovative device products launched every year in the future. ”
Taking this project as an opportunity, Zhangjiang Group will fully cooperate in promoting the early completion, early use and early production of the project in the future. Yuan Tao, Chairman of Zhangjiang Group, said, "We will continue to deepen the win-win cooperation between Jinsai Pharmaceutical and the International Medical Park, and support each other in creating an industrial ecology and promoting coordinated development of project cultivation, industrial investment and industrial activities." It will also accelerate the agglomeration of high-end medical technology industries, create a pharmaceutical innovation industry chain, and work together to build a biomedical industry ecosystem with regional driving force and international competitiveness. ”
Promote the integration of industry, academia, research and medicine
Solve the key problems of maternal and child health
High standards for the pipeline do not mean that R&D is done behind closed doors, and Kinsey is open to all forms of research and commercial collaboration.
At present, Kinsey has created a series of leading R&D technology platforms to drive the development of innovative products through self-research + external cooperation, including protein drug long-term controlled release technology platform, mucosal delivery nucleic acid drug technology platform, ADC drug technology platform, special preparation technology platform, live bacteria drug technology platform, lyase technology platform, focused ultrasound technology platform, intelligent diagnosis technology platform, hydrogel technology platform, injection device technology platform and other technology platforms. At the same time, combined with AI technology, it covers all aspects of innovative drug design, screening, evaluation, process development and preparation, and continuously introduces and promotes new concepts and technologies through the deep integration of production, learning, research and medicine.
Kinsey has established continuous and stable school-enterprise cooperative relations with nearly 20 universities such as Shanghai Jiao Tong University, Zhejiang University, Jilin University, Shenyang Pharmaceutical University, etc., and has carried out various forms of scientific research cooperation with Shanghai Jiao Tong University, Shandong University, Chinese Academy of Sciences Brain Science and Intelligent Technology Excellence Innovation Center and other institutions. It not only establishes a supply chain of first-class talents for enterprises, but also provides a guarantee for the germination and rapid transformation of a large number of scientific and technological achievements.
In addition, Kinsey has cooperated with a number of departments and specialized hospitals related to women and children through multi-center clinical trials, joint application for national projects, provision of innovative technologies and products, and digital systems, and provided the technical capabilities and digital platform capabilities accumulated by Kinsey in the process of product research and development to hospitals in the form of free authorization, which can be used, evaluated and fed back by front-line doctors, and constantly polish and improve scientific research capabilities and digital capabilities in the field of women and children.
For example, Kinsey has cooperated with Fudan Children's Hospital, Beijing Children's Hospital, Wuhan Tongji Hospital, Shanghai Children's Medical Center, Peking Union Medical College Hospital, etc., and has made breakthroughs in the research and development of long-acting growth hormone, indication expansion and post-marketing research. Successfully launched the world's first polyethylene glycol long-acting growth hormone, and published the world's largest sample size of growth hormone treatment research results for idiopathic short stature.
In addition, Kinsey Pharmaceuticals has already upgraded globalization to an important development direction and anchored the world's leading goal. In addition to integrating global resources to bring top innovative products to domestic patients, Kinsey also takes business globalization as its own development strategy, and every existing product and product under development, regardless of size, must consider global operation, and strive to bring the world's leading products to the widest range of patients in the world. At present, Kinsey Pharmaceutical has a relatively mature layout in Asia and has a clear plan to enter the European and American markets.
Source: Pudong release